Nath Bio-Genes (India) Ltd Financials
Company Logo

Nath Bio-Genes (India) Ltd Financial Statement

Nath Bio-Genes (India) Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2025
Revenue284.00
Operating Expense241.27
Net Profit38.21
Net Profit Margin13.45
Earning Per Share20.06
EBIDTA42.74
Effective Tax Rate1.54

Nath Bio-Genes (India) Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Total Revenue Annual362.31
Operating Expenses Annual310.01
Operating Profit Annual57.56
Interest Annual9.65
Depreciation2.16
Net Profit Annual42.14
Tax Annual1.98

Nath Bio-Genes (India) Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Cash Flow at the Beginning75.50
Cash Flow from Operations26.80
Cash Flow from Investing-4.05
Cash Flow from Financing-10.62
Cash Flow at the End87.63

Nath Bio-Genes (India) Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
PBDIT Margin (%)15.92
PBIT Margin (%)14.87
PBT Margin (%)13.34
Net PROFIT Margin (%)11.63
Return On Networth / Equity (%)6.69
Return On Networth /Employed (%)7.25
Return On Assets (%)5.70
Total Debt / Equity (X)0.17
Asset Turnover Ratio (%)0.49

Nath Bio-Genes (India) Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Fixed Assets Annual250.23
Total Current Assets Annual680.55
Non Current Assets Annual336.32
Total Shareholders Funds Annual648.67
Total Assets Annual1,016.87

Nath Bio-Genes (India) Ltd Earning Calls

EPS (INR)

Expected

19.62

Reported

19.58

Surprise

-0.20%

Mar 2025

EPS beaten by -0.20%

Dec 2024

EPS beaten by -46.15%

Sep 2024

EPS beaten by -4.32%

FAQS on Nath Bio-Genes (India) Ltd Financials

As of Aug 23, 2025, Nath Bio-Genes (India) Ltd has a market capitalization of 277.17 Cr. Value Research classifies it as a Small-Cap company.

Yes, Nath Bio-Genes (India) Ltd is with a debt-to-equity ratio of 0.17.

In FY 2024 , Nath Bio-Genes (India) Ltd recorded a total revenue of approximately 362.31 Cr marking a significant milestone in the company's financial performance.

Nath Bio-Genes (India) Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.0% and 0.1% annually, respectively..

Nath Bio-Genes (India) Ltd's current PE ratio is 6.58.

Nath Bio-Genes (India) Ltd's ROCE averaged 7.0% from the FY ending March 2023 to 2025, with a median of 7.1%. It peaked at 7.1% in March 2024, reflecting strong capital efficiency over the period..

Nath Bio-Genes (India) Ltd's latest EBIT is Rs. 53.77 Cr, surpassing the average EBIT of Rs. 50.48 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions